drugset / Trial / NCT06914869
Drug-Drug Interaction Potential of Mavorixafor
RandomizedCrossoverOpen-labelBasic science
Summary
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Timeline
- Start
- 2025-02-18
- Primary completion
- 2025-05-19
- Completion
- 2025-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbamazepine | Small molecule | — | Oral |
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Mavorixafor | Small molecule | — | Oral |
Indications
No indication recorded.